Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker BTEC(USD) LSE
ETF Ticker BTEK(GBP) LSE
ETF Ticker 2B70(EUR) F
ETF Ticker 2B70.DE(EUR) CXE
ETF Ticker BTEC.LS(USD) CXE
ETF Ticker BTEK.LS(GBP) CXE
ETF Ticker BTEC.L(GBP) LSE
ETF Ticker BTEK.L(GBP) LSE

Holdings detail for RIGL

Stock Name	Rigel Pharmaceuticals Inc
Ticker	RIGL(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US7665596034

Show aggregate RIGL holdings

News associated with RIGL

Analysts Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) PT at $38.20: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) has been given an average recommendation of “Hold” by the five analysts that are presently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price […] - 2025-08-19 02:31:03
New York State Common Retirement Fund Raises Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): New York State Common Retirement Fund grew its holdings in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) by 65.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,536 shares of the biotechnology company’s stock after purchasing an additional 2,200 […] - 2025-07-28 04:46:48
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Recommendation of “Hold” from Brokerages: Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) has been given a consensus rating of “Hold” by the five brokerages that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price target among […] - 2025-07-22 07:14:54
Analysts Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Price Target at $36.40: Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) have been given an average rating of “Hold” by the five brokerages that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price […] - 2025-06-30 03:07:05
Bank of America Corp DE Acquires 3,520 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Bank of America Corp DE increased its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) by 12.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 32,166 shares of the biotechnology company’s stock after buying an additional 3,520 shares during the period. Bank of America Corp DE’s holdings in Rigel Pharmaceuticals were worth $541,000 […] - 2025-06-11 04:12:53
Two Sigma Investments LP Makes New Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Two Sigma Investments LP bought a new position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) during the 4th quarter, HoldingsChannel reports. The firm bought 60,913 shares of the biotechnology company’s stock, valued at approximately $1,025,000. Several other institutional investors have also recently made changes to their positions in RIGL. Wells Fargo & […] - 2025-06-06 05:48:57
Nuveen Asset Management LLC Sells 92,110 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Nuveen Asset Management LLC cut its position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) by 80.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 23,053 shares of the biotechnology company’s stock after selling 92,110 shares during the period. Nuveen Asset Management LLC’s holdings in Rigel Pharmaceuticals were worth $388,000 as of […] - 2025-06-06 04:56:48
Analysts Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Price Target at $36.40: Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) have been assigned a consensus rating of “Hold” from the five ratings firms that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price […] - 2025-06-05 02:16:55
Universal Beteiligungs und Servicegesellschaft mbH Invests $676,000 in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 40,200 shares of the biotechnology company’s stock, valued at approximately $676,000. Several other large investors have also […] - 2025-06-04 05:22:50
Squarepoint Ops LLC Purchases 18,159 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Squarepoint Ops LLC lifted its position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) by 40.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 63,416 shares of the biotechnology company’s stock after purchasing an additional 18,159 shares during the quarter. Squarepoint Ops […] - 2025-06-01 06:04:53
Jane Street Group LLC Boosts Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Jane Street Group LLC increased its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) by 144.4% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 62,528 shares of the biotechnology company’s stock after buying an additional 36,939 shares during the quarter. Jane Street Group LLC’s holdings […] - 2025-05-22 04:25:03
Graham Capital Management L.P. Invests $170,000 in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Graham Capital Management L.P. purchased a new position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) during the 4th quarter, HoldingsChannel reports. The fund purchased 10,086 shares of the biotechnology company’s stock, valued at approximately $170,000. Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. […] - 2025-05-20 05:10:53
MetLife Investment Management LLC Acquires 2,014 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): MetLife Investment Management LLC grew its stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) by 19.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,258 shares of the biotechnology company’s stock after purchasing an additional 2,014 shares during the […] - 2025-05-09 05:02:47
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Acquired by Tower Research Capital LLC TRC: Tower Research Capital LLC TRC raised its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) by 1,342.8% during the 4th quarter, Holdings Channel reports. The firm owned 11,874 shares of the biotechnology company’s stock after buying an additional 11,051 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Rigel Pharmaceuticals were worth […] - 2025-05-06 05:09:04
XTX Topco Ltd Buys New Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): XTX Topco Ltd bought a new stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,910 shares of the biotechnology company’s stock, valued at approximately $184,000. XTX Topco Ltd owned 0.06% of Rigel Pharmaceuticals at […] - 2025-04-29 05:01:04
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of “Hold” from Brokerages: Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) have been assigned a consensus rating of “Hold” from the five brokerages that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month […] - 2025-04-18 05:08:54
ExodusPoint Capital Management LP Buys Shares of 15,483 Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): ExodusPoint Capital Management LP bought a new position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) during the 4th quarter, HoldingsChannel reports. The firm bought 15,483 shares of the biotechnology company’s stock, valued at approximately $260,000. A number of other large investors have also recently made changes to their positions in RIGL. FMR […] - 2025-04-14 04:46:55
B. Riley Boosts Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target to $24.00: Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) had its target price boosted by equities researchers at B. Riley from $20.00 to $24.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. B. Riley’s price target would indicate a potential upside of 21.83% from […] - 2025-03-07 06:36:55
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Consensus Target Price from Analysts: Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Get Free Report) have received an average recommendation of “Hold” from the five research firms that are currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month […] - 2025-02-27 06:49:12
China Universal Asset Management Co. Ltd. Takes Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): China Universal Asset Management Co. Ltd. bought a new stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 3,735 shares of the biotechnology company’s stock, valued at approximately $63,000. Several other […] - 2025-02-04 06:53:06

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) RIGL holdings

Date	Number of RIGL Shares Held	Base Market Value of RIGL Shares	Local Market Value of RIGL Shares	Change in RIGL Shares Held	Change in RIGL Base Value	Current Price per RIGL Share Held	Previous Price per RIGL Share Held

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RIGL by Blackrock for IE00BYXG2H39

Show aggregate share trades of RIGL

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-10-06 BUY 90 28.900 29.250 29.215 USD 2,629 22.86
2025-10-03 BUY 210 28.540 29.460 29.368 USD 6,167 22.83
2025-10-02 BUY 30 28.120 29.180 29.074 USD 872 22.80
2025-09-30 BUY 60 28.330 29.210 29.122 USD 1,747 22.74
2025-09-26 BUY 60 28.630 29.000 28.963 USD 1,738 22.67
2025-09-25 BUY 60 28.700 30.080 29.942 USD 1,797 22.64
2025-09-24 SELL -857 30.280 33.890 33.529 USD -28,734 22.60 Loss of -9,369 on sale
2025-09-18 BUY 32 35.110 35.230 35.218 USD 1,127 22.53
2025-09-17 BUY 96 34.220 35.830 35.669 USD 3,424 22.46
2025-09-11 SELL -32 37.820 37.840 37.838 USD -1,211 22.12 Loss of -503 on sale
2025-09-10 BUY 64 36.480 37.560 37.452 USD 2,397 22.04
2025-09-05 SELL -32 41.340 41.350 41.349 USD -1,323 21.73 Loss of -628 on sale
2025-08-29 SELL -96 38.850 39.310 39.264 USD -3,769 21.30 Loss of -1,724 on sale
2025-08-27 BUY 64 39.730 42.080 41.845 USD 2,678 21.08
2025-08-26 SELL -32 41.620 41.730 41.719 USD -1,335 20.95 Loss of -665 on sale
2025-08-25 BUY 32 40.740 42.900 42.684 USD 1,366 20.83
2025-08-20 SELL -128 41.360 41.860 41.810 USD -5,352 20.56 Loss of -2,719 on sale
2025-08-18 BUY 64 40.070 41.250 41.132 USD 2,632 20.32
2025-08-08 SELL -64 31.700 32.400 32.330 USD -2,069 19.84 Loss of -799 on sale
2025-08-05 BUY 32 24.240 24.850 24.789 USD 793 19.67
2025-08-01 SELL -96 21.910 22.030 22.018 USD -2,114 19.64 Loss of -229 on sale
2025-07-30 BUY 128 21.010 21.410 21.370 USD 2,735 19.62
2025-07-17 SELL -64 18.910 19.430 19.378 USD -1,240 19.60 Profit of 14 on sale
2025-07-11 SELL -256 18.880 19.490 19.429 USD -4,974 19.62 Profit of 48 on sale
2025-07-07 BUY 96 18.840 19.050 19.029 USD 1,827 19.64
2025-07-02 BUY 1,760 18.650 19.350 19.280 USD 33,933 19.65
2025-06-25 BUY 64 18.630 18.950 18.918 USD 1,211 19.68
2025-06-11 BUY 66 21.190 22.180 22.081 USD 1,457 19.67
2025-06-10 BUY 66 21.560 22.500 22.406 USD 1,479 19.65
2025-06-04 SELL -33 20.540 20.680 20.666 USD -682 19.59 Loss of -35 on sale
2025-04-23 BUY 33 18.160 19.010 18.925 USD 625 19.73
2025-04-10 SELL -256 16.260 16.970 16.899 USD -4,326 20.11 Profit of 823 on sale
2025-04-08 SELL -32 16.370 17.870 17.720 USD -567 20.22 Profit of 80 on sale
2025-04-07 SELL -32 17.040 18.080 17.976 USD -575 20.27 Profit of 73 on sale
2025-04-04 SELL -165 17.240 17.490 17.465 USD -2,882 20.32 Profit of 470 on sale
2025-04-01 BUY 1,382 17.150 17.830 17.762 USD 24,547 20.40
2025-03-31 SELL -84 17.990 18.450 18.404 USD -1,546 20.44 Profit of 171 on sale
2025-03-14 SELL -464 20.130 20.330 20.310 USD -9,424 20.60 Profit of 137 on sale
2025-03-07 SELL -58 20.520 20.650 20.637 USD -1,197 20.68 Profit of 2 on sale
2025-03-04 SELL -29 22.080 22.400 22.368 USD -649 20.68 Loss of -49 on sale
2025-02-25 BUY 58 21.500 21.870 21.833 USD 1,266 20.46
2025-02-19 SELL -29 20.620 21.200 21.142 USD -613 20.42 Loss of -21 on sale
2025-02-13 BUY 84 20.860 21.120 21.094 USD 1,772 20.31
2025-02-12 BUY 28 20.820 20.970 20.955 USD 587 20.29
2025-02-11 BUY 112 20.840 21.110 21.083 USD 2,361 20.27
2025-01-17 BUY 116 20.130 20.520 20.481 USD 2,376 16.90
2025-01-16 BUY 112 17.350 18.080 18.007 USD 2,017 16.84
2025-01-10 SELL -56 16.250 16.310 16.304 USD -913 16.61 Profit of 17 on sale
2025-01-08 SELL -116 16.250 17.070 16.988 USD -1,971 17.32 Profit of 39 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-10-06	BUY	90	28.900	29.250	29.215	USD 2,629	22.86
2025-10-03	BUY	210	28.540	29.460	29.368	USD 6,167	22.83
2025-10-02	BUY	30	28.120	29.180	29.074	USD 872	22.80
2025-09-30	BUY	60	28.330	29.210	29.122	USD 1,747	22.74
2025-09-26	BUY	60	28.630	29.000	28.963	USD 1,738	22.67
2025-09-25	BUY	60	28.700	30.080	29.942	USD 1,797	22.64
2025-09-24	SELL	-857	30.280	33.890	33.529	USD -28,734	22.60 Loss of -9,369 on sale
2025-09-18	BUY	32	35.110	35.230	35.218	USD 1,127	22.53
2025-09-17	BUY	96	34.220	35.830	35.669	USD 3,424	22.46
2025-09-11	SELL	-32	37.820	37.840	37.838	USD -1,211	22.12 Loss of -503 on sale
2025-09-10	BUY	64	36.480	37.560	37.452	USD 2,397	22.04
2025-09-05	SELL	-32	41.340	41.350	41.349	USD -1,323	21.73 Loss of -628 on sale
2025-08-29	SELL	-96	38.850	39.310	39.264	USD -3,769	21.30 Loss of -1,724 on sale
2025-08-27	BUY	64	39.730	42.080	41.845	USD 2,678	21.08
2025-08-26	SELL	-32	41.620	41.730	41.719	USD -1,335	20.95 Loss of -665 on sale
2025-08-25	BUY	32	40.740	42.900	42.684	USD 1,366	20.83
2025-08-20	SELL	-128	41.360	41.860	41.810	USD -5,352	20.56 Loss of -2,719 on sale
2025-08-18	BUY	64	40.070	41.250	41.132	USD 2,632	20.32
2025-08-08	SELL	-64	31.700	32.400	32.330	USD -2,069	19.84 Loss of -799 on sale
2025-08-05	BUY	32	24.240	24.850	24.789	USD 793	19.67
2025-08-01	SELL	-96	21.910	22.030	22.018	USD -2,114	19.64 Loss of -229 on sale
2025-07-30	BUY	128	21.010	21.410	21.370	USD 2,735	19.62
2025-07-17	SELL	-64	18.910	19.430	19.378	USD -1,240	19.60 Profit of 14 on sale
2025-07-11	SELL	-256	18.880	19.490	19.429	USD -4,974	19.62 Profit of 48 on sale
2025-07-07	BUY	96	18.840	19.050	19.029	USD 1,827	19.64
2025-07-02	BUY	1,760	18.650	19.350	19.280	USD 33,933	19.65
2025-06-25	BUY	64	18.630	18.950	18.918	USD 1,211	19.68
2025-06-11	BUY	66	21.190	22.180	22.081	USD 1,457	19.67
2025-06-10	BUY	66	21.560	22.500	22.406	USD 1,479	19.65
2025-06-04	SELL	-33	20.540	20.680	20.666	USD -682	19.59 Loss of -35 on sale
2025-04-23	BUY	33	18.160	19.010	18.925	USD 625	19.73
2025-04-10	SELL	-256	16.260	16.970	16.899	USD -4,326	20.11 Profit of 823 on sale
2025-04-08	SELL	-32	16.370	17.870	17.720	USD -567	20.22 Profit of 80 on sale
2025-04-07	SELL	-32	17.040	18.080	17.976	USD -575	20.27 Profit of 73 on sale
2025-04-04	SELL	-165	17.240	17.490	17.465	USD -2,882	20.32 Profit of 470 on sale
2025-04-01	BUY	1,382	17.150	17.830	17.762	USD 24,547	20.40
2025-03-31	SELL	-84	17.990	18.450	18.404	USD -1,546	20.44 Profit of 171 on sale
2025-03-14	SELL	-464	20.130	20.330	20.310	USD -9,424	20.60 Profit of 137 on sale
2025-03-07	SELL	-58	20.520	20.650	20.637	USD -1,197	20.68 Profit of 2 on sale
2025-03-04	SELL	-29	22.080	22.400	22.368	USD -649	20.68 Loss of -49 on sale
2025-02-25	BUY	58	21.500	21.870	21.833	USD 1,266	20.46
2025-02-19	SELL	-29	20.620	21.200	21.142	USD -613	20.42 Loss of -21 on sale
2025-02-13	BUY	84	20.860	21.120	21.094	USD 1,772	20.31
2025-02-12	BUY	28	20.820	20.970	20.955	USD 587	20.29
2025-02-11	BUY	112	20.840	21.110	21.083	USD 2,361	20.27
2025-01-17	BUY	116	20.130	20.520	20.481	USD 2,376	16.90
2025-01-16	BUY	112	17.350	18.080	18.007	USD 2,017	16.84
2025-01-10	SELL	-56	16.250	16.310	16.304	USD -913	16.61 Profit of 17 on sale
2025-01-08	SELL	-116	16.250	17.070	16.988	USD -1,971	17.32 Profit of 39 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RIGL

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	144,753	802	229,038	63.2%
2025-09-18	147,530	0	281,770	52.4%
2025-09-17	52,223	1,003	198,002	26.4%
2025-09-16	65,754	12	187,523	35.1%
2025-09-15	97,953	535	236,854	41.4%
2025-09-12	56,602	0	136,954	41.3%
2025-09-11	98,193	0	260,347	37.7%
2025-09-10	109,502	8,982	306,819	35.7%
2025-09-09	167,660	23,245	497,856	33.7%
2025-09-08	204,171	0	370,806	55.1%
2025-09-05	83,785	0	155,317	53.9%
2025-09-04	170,996	0	314,484	54.4%
2025-09-03	111,609	0	342,236	32.6%
2025-09-02	57,307	1,727	169,286	33.9%
2025-08-29	78,775	0	352,589	22.3%
2025-08-28	44,629	0	287,004	15.5%
2025-08-27	72,941	10	321,461	22.7%
2025-08-26	77,389	400	282,727	27.4%
2025-08-25	110,959	659	357,556	31.0%
2025-08-22	121,093	157	344,175	35.2%
2025-08-21	138,794	94	359,496	38.6%
2025-08-20	157,200	200	441,297	35.6%
2025-08-19	94,280	904	292,706	32.2%
2025-08-18	190,781	431	490,813	38.9%
2025-08-15	109,259	325	309,453	35.3%
2025-08-14	135,757	50	349,573	38.8%
2025-08-13	163,835	39	468,647	35.0%
2025-08-12	146,625	0	426,312	34.4%
2025-08-11	165,221	0	454,991	36.3%
2025-08-08	159,548	165	605,473	26.4%
2025-08-07	104,322	502	376,276	27.7%
2025-08-06	239,356	589	958,301	25.0%
2025-08-05	212,547	282	379,821	56.0%
2025-08-04	73,556	0	181,050	40.6%
2025-08-01	36,827	144	67,857	54.3%
2025-07-31	29,849	10	66,877	44.6%
2025-07-30	43,855	60	108,743	40.3%
2025-07-29	97,496	0	126,847	76.9%
2025-07-28	27,364	100	49,007	55.8%
2025-07-25	20,997	35	56,983	36.8%
2025-07-24	24,251	300	55,810	43.5%
2025-07-23	61,029	0	93,138	65.5%
2025-07-22	48,465	1,774	75,678	64.0%
2025-07-21	40,131	428	72,458	55.4%
2025-07-18	24,110	34	39,120	61.6%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE